Want to see A full AI Analyst Report?
Earnings Data
Report Date
Aug 18, 2026After Close (Confirmed)
Period Ending
2026 (Q3)Consensus EPS Forecast
1.49Last Year’s EPS
1.37Same Quarter Last Year
Strong Buy
Based on 16 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call presented a strong operational and financial performance: revenue, margins, and EPS all beat expectations, management raised full‑year guidance, and multiple indicators (instrument orders, segment outperformance, pricing, supply chain resilience and product innovation) point to durable momentum. Near-term challenges include China softness, food and academia/government weakness, and inflationary/geopolitical cost pressures that add uncertainty. On balance the positive operational wins and upgraded guidance outweigh the cited headwinds.Company Guidance
Revenue and Growth Beat
Q2 revenue of $1.83B, core (organic constant currency) growth of 6.3% YoY (reported +10% with a 3.7% currency tailwind), beating the high end of guidance by 80 bps.
Margin Expansion and EPS Outperformance
Non-GAAP operating margin of 26.4% (+130 bps YoY, +180 bps sequential) and EPS of $1.49 (+14% YoY), both above prior guidance (EPS beat by $0.07).
Upgraded Full-Year Outlook
FY26 revenue guidance raised to $7.39B–$7.49B (core growth 4.5%–6.0%, midpoint +30 bps) and EPS guidance increased to $6.00–$6.10 (midpoint +$0.08), with operating margin expansion guidance raised to ~85 bps at midpoint.
Strong Segment Performance — AMG and LDG
Applied Markets Group (AMG) grew 11% core and Life Sciences & Diagnostics Group (LDG) grew 9% core, both ahead of expectations; spectroscopy (AMG) showed double-digit strength driven by semiconductor-related demand.
Instrument Strength and Replacement Momentum
Instrument revenue delivered high-single-digit growth with market-leading low-double-digit growth in LC/LCMS and GC; book-to-bill remained >1.0 for the ninth consecutive quarter indicating healthy order momentum.
Innovation and Product Launches
Announced new product launches including the 9500 triple-quad ICP-MS and upgraded flagship GCs (up to 30% faster oven cool down), plus OpenLab CDS v3.0; Altura Ultro Inert LC columns grew >50% sequentially and reached 75% penetration of top 20 biopharma accounts.
Pricing, Ignite and Supply Chain Gains
Strategic pricing contributed ~200 bps in Q2 (exceeding initial full-year target of 100 bps); tariff task force fully mitigated incremental tariffs; manufacturing overhead reduced by >50 bps YoY; digital orders grew 9% overall (>20% ex-China).
Cash Flow and Balance Sheet Strength
Operating cash flow of $277M in Q2, capex $76M, $65M share repurchases and $72M dividends paid in the quarter, and net leverage of 0.7x, maintaining a strong balance sheet.
A Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
A Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 27, 2026 | $115.62 | $135.12 | +16.87% |
Feb 25, 2026 | $124.20 | $120.46 | -3.01% |
Oct 31, 2025 | $145.49 | $143.83 | -1.14% |
Aug 27, 2025 | $117.75 | $123.97 | +5.28% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Agilent Technologies (A) report earnings?
Agilent Technologies (A) is schdueled to report earning on Aug 18, 2026, After Close (Confirmed).
What is Agilent Technologies (A) earnings time?
Agilent Technologies (A) earnings time is at Aug 18, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is A EPS forecast?
A EPS forecast for the fiscal quarter 2026 (Q3) is 1.49.
